Rezolute completes enrollment in Phase 3 tumor hyperinsulinism study
Tweet Send to a Friend
Rezolute, Inc. (NASDAQ: RZLT) announced the completion of enrollment in its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




